CA2000355A1 - Recepteur gamma iii du fragment fc chez les humains - Google Patents

Recepteur gamma iii du fragment fc chez les humains

Info

Publication number: CA2000355A1
Authority: CA; Canada
Prior art keywords: ser; ala; riii; cells; leu
Prior art date: 1989-01-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002000355A

Other languages

English (en)

Inventor

Donald A. Peltz

Kevin W. Moore

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-01-19

Filing date

1989-10-10

Publication date

1990-07-19

1989-10-10 Application filed by Individual filed Critical Individual

1990-07-19 Publication of CA2000355A1 publication Critical patent/CA2000355A1/fr

Status Abandoned legal-status Critical Current

Links

102000009490 IgG Receptors Human genes 0.000 title 1
108010073807 IgG Receptors Proteins 0.000 title 1
239000012528 membrane Substances 0.000 claims abstract description 11
150000007523 nucleic acids Chemical class 0.000 claims abstract description 9
108020004707 nucleic acids Proteins 0.000 claims abstract description 8
102000039446 nucleic acids Human genes 0.000 claims abstract description 8
208000028622 Immune thrombocytopenia Diseases 0.000 claims abstract description 7
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims abstract 2
108090000623 proteins and genes Proteins 0.000 claims description 43
102000004169 proteins and genes Human genes 0.000 claims description 36
150000001413 amino acids Chemical class 0.000 claims description 22
239000002299 complementary DNA Substances 0.000 claims description 17
238000000034 method Methods 0.000 claims description 14
229920001184 polypeptide Polymers 0.000 claims description 11
108090000765 processed proteins & peptides Proteins 0.000 claims description 11
102000004196 processed proteins & peptides Human genes 0.000 claims description 11
239000013598 vector Substances 0.000 claims description 10
125000003275 alpha amino acid group Chemical group 0.000 claims description 7
241000282693 Cercopithecidae Species 0.000 claims description 3
230000037396 body weight Effects 0.000 claims 1
238000001990 intravenous administration Methods 0.000 claims 1
238000002372 labelling Methods 0.000 claims 1
210000002966 serum Anatomy 0.000 abstract description 13
238000003556 assay Methods 0.000 abstract description 7
230000007812 deficiency Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 43
235000018102 proteins Nutrition 0.000 description 28
229940024606 amino acid Drugs 0.000 description 24
235000001014 amino acid Nutrition 0.000 description 23
125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 20
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 19
230000014509 gene expression Effects 0.000 description 16
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 8
239000002609 medium Substances 0.000 description 7
239000000203 mixture Substances 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
238000012552 review Methods 0.000 description 7
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
210000004962 mammalian cell Anatomy 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
239000000243 solution Substances 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 5
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 5
101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 5
239000003550 marker Substances 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 4
210000001772 blood platelet Anatomy 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 4
MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 4
108020004705 Codon Proteins 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
-1 their muteins Proteins 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102000004533 Endonucleases Human genes 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000008827 biological function Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000000423 cell based assay Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229940027941 immunoglobulin g Drugs 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
235000006109 methionine Nutrition 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
230000035772 mutation Effects 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
230000010473 stable expression Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
AUXMWYRZQPIXCC-KNIFDHDWSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O AUXMWYRZQPIXCC-KNIFDHDWSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
KSBHCUSPLWRVEK-ZLUOBGJFSA-N Asn-Asn-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KSBHCUSPLWRVEK-ZLUOBGJFSA-N 0.000 description 1
TWXZVVXRRRRSLT-IMJSIDKUSA-N Asn-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O TWXZVVXRRRRSLT-IMJSIDKUSA-N 0.000 description 1
NNDSLVWAQAUPPP-GUBZILKMSA-N Asn-Met-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)N)N NNDSLVWAQAUPPP-GUBZILKMSA-N 0.000 description 1
CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108010032597 Cohn fraction II Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
BPHKULHWEIUDOB-FXQIFTODSA-N Cys-Gln-Gln Chemical compound SC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O BPHKULHWEIUDOB-FXQIFTODSA-N 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
JEFZIKRIDLHOIF-BYPYZUCNSA-N Gln-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(O)=O JEFZIKRIDLHOIF-BYPYZUCNSA-N 0.000 description 1
FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
SYIPVNMWBZXKMU-HJPIBITLSA-N His-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CN=CN2)N SYIPVNMWBZXKMU-HJPIBITLSA-N 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
ZJWIXBZTAAJERF-IHRRRGAJSA-N Lys-Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZJWIXBZTAAJERF-IHRRRGAJSA-N 0.000 description 1
108010079364 N-glycylalanine Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
VBKBDLMWICBSCY-IMJSIDKUSA-N Ser-Asp Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O VBKBDLMWICBSCY-IMJSIDKUSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 1
FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
NQIHMZLGCZNZBN-PXNSSMCTSA-N Trp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-PXNSSMCTSA-N 0.000 description 1
UUJHRSTVQCFDPA-UFYCRDLUSA-N Tyr-Tyr-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 UUJHRSTVQCFDPA-UFYCRDLUSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
230000002096 anti-tetanic effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
108010068380 arginylarginine Proteins 0.000 description 1
108010038633 aspartylglutamate Proteins 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
108010078144 glutaminyl-glycine Proteins 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
108010028295 histidylhistidine Proteins 0.000 description 1
229940098197 human immunoglobulin g Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000001738 isopycnic centrifugation Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
150000002742 methionines Chemical class 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
230000007096 poisonous effect Effects 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
108010077112 prolyl-proline Proteins 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
238000002764 solid phase assay Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
108010061238 threonyl-glycine Proteins 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
230000003582 thrombocytopenic effect Effects 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
108010045269 tryptophyltryptophan Proteins 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000007306 turnover Effects 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1

Landscapes

Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA002000355A 1989-01-19 1989-10-10 Recepteur gamma iii du fragment fc chez les humains Abandoned CA2000355A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30003989A	1989-01-19	1989-01-19
US300,039		1989-01-19

Publications (1)

Publication Number	Publication Date
CA2000355A1 true CA2000355A1 (fr)	1990-07-19

Family

ID=23157428

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002000355A Abandoned CA2000355A1 (fr)	1989-01-19	1989-10-10	Recepteur gamma iii du fragment fc chez les humains

Country Status (1)

Country	Link
CA (1)	CA2000355A1 (fr)

1989
- 1989-10-10 CA CA002000355A patent/CA2000355A1/fr not_active Abandoned

Legal Events

Date	Code	Title	Description
1992-04-12	FZDE	Dead

Publication	Publication Date	Title
EP0791653B1 (fr)	2006-03-22	Récepteur du Fc-gamma III humain
EP0367566B1 (fr)	1997-05-14	Récepteurs d'interleukine-4
US7101965B2 (en)	2006-09-05	Peptides of IL-2
JP2007267750A (ja)	2007-10-18	可溶性ｉｌ−ｔｉｆ／ｉｌ−２２レセプターまたはｉｌ−ｔｉｆ／ｉｌ−２２に結合する結合タンパク質をコードする単離された核酸分子、およびその使用
AU723494B2 (en)	2000-08-31	Mutant human growth hormones and their uses
Khromykh et al.	2007	Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells
JPH10502372A (ja)	1998-03-03	共通のサイトカイン受容体ガンマ鎖を操作することによるｔ細胞応答の変調方法
JPH09132598A (ja)	1997-05-20	ヒトインターロイキン−１２受容体
JP2001523446A (ja)	2001-11-27	Ｔｈ２細胞枯渇、組成物、方法
JP4360902B2 (ja)	2009-11-11	融合タンパク質
US5767077A (en)	1998-06-16	Human Fc-γ receptor III
CA2000355A1 (fr)	1990-07-19	Recepteur gamma iii du fragment fc chez les humains
KR100272867B1 (ko)	2000-11-15	Tpo활성을 갖는 단백질
JPH07505524A (ja)	1995-06-22	Ｉｆｎ受容体認識因子，そのタンパク質配列および使用方法
HK1001403C (en)	2006-06-02	Human fc-gamma receptor iii
HK1001403B (en)	2006-06-02	Human fc-gamma receptor iii
KR100332138B1 (ko)	2002-08-28	인터루킨-4수용체를포함하는,바이러스,기생충,세균감염증또는진균감염증질환의치료및예방용약제학적조성물
CA1340761C (fr)	1999-09-21	Recepteurs d'interleukine 4
Yildirim	1996	New binding activities for interleukin-2
Sharief	1992	The importance of interleukin-2 and its soluble receptor in patients with multiple sclerosis and other inflammatory diseases of the central nervous system
Zupan	1992	Truncated forms of the human nerve growth factor receptor
EP1230357A2 (fr)	2002-08-14	Genes exprimes de facon differentielle dans les cellules tr1 et leur utilisation dans la preparation de compositions
US20080227953A1 (en)	2008-09-18	c-Mpl LIGAND POLYPEPTIDE
JP2003519162A (ja)	2003-06-17	Ｐｐ１４融合蛋白質並びに該蛋白質の製造及び使用方法
JPH11514968A (ja)	1999-12-21	筋無力症の処置のためのヌクレオチドおよびペプチド配列